Biomx Inc (PHGE)
BiomX Inc. is a clinical-stage biopharmaceutical company focused on developing phage-based therapies that use natural and engineered bacteriophages to selectively target harmful bacteria linked to chronic diseases. Its programs include a fixed-cocktail approach, designed as a single product with selected phages to address multiple bacterial strains, and a personalized approach that matches an optimal phage from a larger library to individual patients. The company’s pipeline includes BX011, a multi-phage cocktail in Phase 2a testing for diabetic foot infections, and BX211, a phage therapy in Phase 2 development for diabetic foot osteomyelitis. Founded in 2015, BiomX is based in Dover, Delaware. The listed security is common stock on the NYSE.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-PHGE
|
$2.02
|
8.9% Upside
|
Fair
|
$3,040 164,224.3% Upside
|
Not available
|
Bargain
|
Weak
|
0.0%
|
November 13, 2026
|
1.1x
|
14.9x
|
4.944 M
|
19.007 M
|
7.0%
|
91.4%
|
-151.2
|
39.9%
|
